Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals (TARS) reported a Form 144 notice for a proposed sale of insider-held Class A shares. The filer notifies an intended sale of 27,116 Class A shares on Nasdaq, with an aggregate market value of $1,546,000 and approximately 42,214,106 shares outstanding, implying the proposed block represents about 0.064% of outstanding stock. The securities were acquired in a private placement on 12/13/2019 from William Link and were paid for in cash. The intended sale date listed is 09/08/2025. The filer states there are no sales in the past three months and affirms no undisclosed material adverse information.
RTW Investments, LP and Roderick Wong report beneficial ownership of 3,424,180 shares of Tarsus Pharmaceuticals common stock, representing 8.1% of the outstanding shares based on 42,014,237 shares outstanding as reported in the companys quarterly report dated April 24, 2025. The shares are held by the RTW Funds, for which RTW Investments is the investment adviser, and Dr. Wong reports the same aggregate holding on behalf of those funds.
The filing shows no sole voting or dispositive power (0 shares) and shared voting and dispositive power over the 3,424,180 shares. The Reporting Persons certify the securities are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer.
Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals (TARS), reported sales of common stock on 08/11/2025 as shown on this Form 4. The filing lists dispositions of 53,635 and 6,000 shares and shows a transaction price of $50 where indicated, with reported beneficial ownership of 818,106 shares following the transactions. The sales were effected automatically under a Rule 10b5-1 trading plan adopted December 12, 2024. Azamian is trustee of the Bobak Azamian Living Trust (established April 16, 2018) and has voting and dispositive power over the trust shares. The Form 4 was signed by an attorney-in-fact on 08/13/2025.
Tarsus Pharmaceuticals filed a Form 144 reporting a proposed sale of 6,000 shares of common stock through Merrill Lynch in Newport Beach with an aggregate market value of $300,000. The filing lists 42,214,106 shares outstanding and an approximate sale date of 08/11/2025. The shares were acquired on 01/13/2017 in a private placement from Tarsus Pharmaceuticals and were paid for in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.